In September, the Trump administration announced ambitious plans regarding autism treatment. They highlighted leucovorin, a generic drug, as a potential option. Marty Makary, the FDA commissioner, claimed there was a “growing body of evidence” suggesting that leucovorin could be beneficial. He even suggested that it might help a significant percentage of children with autism.
“Hundreds of thousands of kids, in my opinion, will benefit,” he stated confidently during a White House press event.
These claims prompted a surge in the prescribing of leucovorin. A study in The Lancet revealed that prescriptions for children aged 5 to 17 increased by 71% in the three months following the administration’s announcements.
However, the FDA later clarified that they did not share this optimistic view. They approved leucovorin for a specific genetic issue, cerebral folate deficiency (CFD), but not for autism treatment. Senior FDA officials emphasized they had found little evidence supporting its use for autism, narrowing their focus solely on the rare condition caused by a genetic mutation in the folate receptor 1 gene.
Interestingly, the conversation around leucovorin and autism is part of a larger trend. Recent healthcare discussions often highlight the importance of evidence-based treatment. This shift reflects growing public demand for transparency and accountability in medical claims.
Historically, similar situations have occurred. In the past, certain treatments have been touted without robust supporting evidence, only for further research to clarify their limited effectiveness.
Social media reactions to the recent announcements have been mixed. While some parents expressed hope about potential new treatments, others raised concerns over the rush to prescribe medications without thorough research.
Overall, the conversation about autism treatment continues to evolve, and it shows the importance of ongoing research and communication in healthcare. It’s crucial to remain informed and cautious as new treatments are discussed.
For more on the FDA’s approval process, you can read about it here.
